SG10201900879PA - Cdca1-derived peptide and vaccine containing same - Google Patents

Cdca1-derived peptide and vaccine containing same

Info

Publication number
SG10201900879PA
SG10201900879PA SG10201900879PA SG10201900879PA SG10201900879PA SG 10201900879P A SG10201900879P A SG 10201900879PA SG 10201900879P A SG10201900879P A SG 10201900879PA SG 10201900879P A SG10201900879P A SG 10201900879PA SG 10201900879P A SG10201900879P A SG 10201900879PA
Authority
SG
Singapore
Prior art keywords
peptides
present
cells
cdca1
provides
Prior art date
Application number
SG10201900879PA
Inventor
Takuya Tsunoda
Ryuji Osawa
Sachiko Yamashita
Tomohisa Watanabe
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of SG10201900879PA publication Critical patent/SG10201900879PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Abstract

CDCA1-DERIVED PEPTIDE AND VACCINE CONTAINING SAME The present invention provides CDCA1-derived epitope peptides having the ability to induce 5 cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or 10 preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen- presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided. [FIG.4] 15
SG10201900879PA 2014-08-04 2015-07-31 Cdca1-derived peptide and vaccine containing same SG10201900879PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014158924 2014-08-04
JP2014158923 2014-08-04
JP2014158922 2014-08-04

Publications (1)

Publication Number Publication Date
SG10201900879PA true SG10201900879PA (en) 2019-03-28

Family

ID=55263774

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201700839SA SG11201700839SA (en) 2014-08-04 2015-07-31 Cdca1-derived peptide and vaccine containing same
SG10201900879PA SG10201900879PA (en) 2014-08-04 2015-07-31 Cdca1-derived peptide and vaccine containing same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201700839SA SG11201700839SA (en) 2014-08-04 2015-07-31 Cdca1-derived peptide and vaccine containing same

Country Status (14)

Country Link
US (1) US10676514B2 (en)
EP (2) EP3178839B1 (en)
JP (3) JP6700512B2 (en)
KR (1) KR20170040315A (en)
CN (3) CN113321703A (en)
AU (2) AU2015300258B2 (en)
BR (1) BR112017002212A2 (en)
CA (1) CA2956132A1 (en)
IL (1) IL250215B (en)
MX (1) MX2017001650A (en)
RU (1) RU2699543C2 (en)
SG (2) SG11201700839SA (en)
TW (2) TWI719944B (en)
WO (1) WO2016021508A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101943978B1 (en) * 2017-12-28 2019-01-30 주식회사 하이센스바이오 Novel peptide
TW202023581A (en) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 Cdca1-derived peptide and vaccine containing same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (en) 1990-08-29 2005-10-24 Genpharm Int Transgenic, non-human animals capable of forming heterologous antibodies
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en) 1996-07-26 2001-09-25 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (en) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med NOVEL METHOD FOR SENSITIZING ANTIGEN PRESENTING CELLS AND NOVEL MEANS FOR IMPLEMENTING THE METHOD
US6573243B1 (en) * 1997-08-25 2003-06-03 Suntory Limited Pompilid wasp-derived neuropeptides
KR100653590B1 (en) 1998-06-25 2006-12-04 교고 이또 Tumor antigen peptides originating in cyclophilin b
AU2002240818C1 (en) 2001-03-14 2008-11-06 Agilent Technologies, Inc. MHC molecule constructs and their uses for diagnosis and therapy
CN1898563B (en) 2003-09-24 2011-11-23 肿瘤疗法科学股份有限公司 Method of diagnosing breast cancer
EP1730534A2 (en) * 2004-03-24 2006-12-13 Oncotherapy Science, Inc. Compositions and methods for treating lung cancer
US7915036B2 (en) 2004-09-13 2011-03-29 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions comprising T cell receptors and methods of use thereof
WO2006085684A2 (en) 2005-02-10 2006-08-17 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP2295570A1 (en) 2005-07-27 2011-03-16 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
EP2311986B1 (en) 2005-07-27 2015-04-15 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US7943295B2 (en) 2005-07-29 2011-05-17 Oncotherapy Science, Inc. Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
KR101130597B1 (en) 2005-09-13 2012-04-02 다카라 바이오 가부시키가이샤 T-cell receptor and nucleic acid encoding the receptor
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
JP5493076B2 (en) 2007-08-20 2014-05-14 オンコセラピー・サイエンス株式会社 CDCA1 peptide and drug containing the same
TWI526219B (en) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Cdca1 epitope peptides and vaccines containing the same
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
EP2872532A4 (en) 2012-07-10 2016-04-13 Oncotherapy Science Inc Cdca1 epitope peptides for th1 cells and vaccines containing the same
JP5923536B2 (en) 2014-03-13 2016-05-24 株式会社三共 Game machine
JP5829296B2 (en) 2014-03-13 2015-12-09 株式会社三共 Game machine
JP5805242B2 (en) 2014-03-13 2015-11-04 株式会社ユニバーサルエンターテインメント Game machine

Also Published As

Publication number Publication date
RU2017106888A3 (en) 2019-02-22
CN107074908B (en) 2021-10-15
EP3178839A1 (en) 2017-06-14
AU2015300258A1 (en) 2017-02-23
IL250215A0 (en) 2017-03-30
JP2020062031A (en) 2020-04-23
JP2022050382A (en) 2022-03-30
AU2020202681A1 (en) 2020-05-14
IL250215B (en) 2021-02-28
EP3178839A4 (en) 2018-06-20
JP6999185B2 (en) 2022-02-04
WO2016021508A1 (en) 2016-02-11
SG11201700839SA (en) 2017-03-30
CN113321703A (en) 2021-08-31
MX2017001650A (en) 2017-04-27
US20180079791A1 (en) 2018-03-22
KR20170040315A (en) 2017-04-12
AU2015300258B2 (en) 2020-03-12
RU2017106888A (en) 2018-09-10
BR112017002212A2 (en) 2017-11-21
JPWO2016021508A1 (en) 2017-05-18
EP4282883A3 (en) 2024-04-24
TWI719944B (en) 2021-03-01
JP6700512B2 (en) 2020-05-27
JP7266318B2 (en) 2023-04-28
RU2699543C2 (en) 2019-09-06
TW202016146A (en) 2020-05-01
EP4282883A2 (en) 2023-11-29
CA2956132A1 (en) 2016-02-11
TW201613952A (en) 2016-04-16
CN107074908A (en) 2017-08-18
AU2015300258A8 (en) 2017-03-02
US10676514B2 (en) 2020-06-09
EP3178839B1 (en) 2023-10-04
AU2020202681B2 (en) 2021-07-01
CN113321704A (en) 2021-08-31
TWI745810B (en) 2021-11-11
AU2015300258A2 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
MX2022001755A (en) Cyclic di-nucleotide compounds and methods of use.
MX2022003698A (en) Nanoparticle compositions and methods for immunotherapy.
MX2023003875A (en) Formulation of a peptide vaccine.
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
MA40539A (en) Methods for formulating antibody drug conjugate compositions
MX2018012618A (en) Oral pharmaceutical compositions of mesalazine.
MX366365B (en) Kntc2 peptides and vaccines containing the same.
MX2021010041A (en) Pharmaceutical compositions comprising akt protein kinase inhibitors.
MX2017009289A (en) Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same.
UA114298C2 (en) Tork peptides and vaccines including the same
NZ730708A (en) Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
SG10201900933YA (en) Koc1-derived peptide and vaccine including same
MX2022006022A (en) Depdc1-derived peptide and vaccine containing same.
MX362912B (en) Ube2t peptides and vaccines containing the same.
EP4219525A3 (en) Foxm1-derived peptide, and vaccine including same
SG10201900879PA (en) Cdca1-derived peptide and vaccine containing same
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2015149016A3 (en) Breast and ovarian cancer vaccines
SG10201900835XA (en) Urlc10-derived peptide and vaccine containing same
MX2021001357A (en) Cdca1-derived peptide and vaccine containing same.
MX2017003949A (en) Novel peptide derivatives and uses thereof.
TW201613563A (en) Bi-layer tablet formulations of cyclophosphamide and CAPECITABINE and highly fractionated METRONOMIC administration thereof
BR112018006894A2 (en) The vaccine containing MPHOSPH1 origin peptide and it
MX2012011666A (en) Cluap1 peptides and vaccines including the same.